Biology Reference
In-Depth Information
Finsterer J, St
ollberger C (2003) The heart in human dystrophinopathies. Cardiology 99:1-19
Firestein BL, Bredt DS (1999) Interaction of neuronal nitric-oxide synthase and phosphofructo-
kinase-M. J Biol Chem 274:10545-10550
Frankel KA, Rosser RJ (1976) The pathology of the heart in progressive muscular dystrophy:
epimyocardial fibrosis. Hum Pathol 7:375-386
Hillier BJ, Christopherson KS, Prehoda KE, Bredt DS, Lim WA (1999) Unexpected modes of
PDZ domain scaffolding revealed by structure of nNOS-syntrophin complex. Science
284:812-815
Hoffman EP, Brown RH Jr, Kunkel LM (1987) Dystrophin: the protein product of the Duchenne
muscular dystrophy locus. Cell 51:919-928
Hofmann F, Bernhard D, Lukowski R, Weinmeister P (2009) cGMP regulated protein kinases
(cGK). Handb Exp Pharmacol 191:137-162
Ishikawa Y, Bach JR, Minami R (1999) Cardioprotection for Duchenne's muscular dystrophy. Am
Heart J 137:895-902
Ito K, Kimura S, Ozasa S, Matsukura M, Ikezawa M, Yoshioka K, Ueno H, Suzuki M, Araki K,
Yamamura K, Miwa T, Dickson G, Thomas GD, Miike T (2006) Smooth muscle-specific
dystrophin expression improves aberrant vasoregulation in mdx mice. Hum Mol Genet
15:2266-2275
Jerusalem F, Engel AG, Gomez MR (1974) Duchenne dystrophy I. morphometric study of the
muscle microvasculature. Brain 97:115-122
Kameya S, Miyagoe Y, Nonaka I, Ikemoto T, Endo M, Hanaoka K, Nabeshima Y, Takeda S
(1999) alpha1-syntrophin gene disruption results in the absence of neuronal-type nitric-oxide
synthase at
€
the sarcolemma but does not
induce muscle degeneration. J Biol Chem
274:2193-2200
Khairallah M, Khairallah R, Young ME, Dyck JR, Petrof BJ, Des Rosiers C (2007) Metabolic and
signaling alterations in dystrophin-deficient hearts precede overt cardiomyopathy. J Mol Cell
Cardiol 43:119-1129
Khairallah M, Khairallah RJ, Young ME, Allen BG, Gillis MA, Danialou G, Deschepper CF,
Petrof BJ, Des Rosiers C (2008) Sildenafil and cardiomyocyte-specific cGMP signaling
prevent cardiomyopathic changes associated with dystrophin deficiency. Proc Natl Acad Sci
USA 105:7028-7033
Kobayashi YM, Rader EP, Crawford RW, Iyengar NK, Thedens DR, Faulkner JA, Parikh SV,
Weiss RM, Chamberlain JS, Moore SA, Campbell KP (2008) Sarcolemma-localized nNOS is
required to maintain activity after mild exercise. Nature 456:511-515
Koenig M, Monaco AP, Kunkel LM (1988) The complete sequence of dystrophin predicts a rod-
shaped cytoskeletal protein. Cell 53:219-228
Lai Y, Thomas GD, Yue Y, Yang HT, Li D, Long C, Judge L, Bostick B, Chamberlain JS,
Terjung RL, Duan D (2009) Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS
to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy.
J Clin Invest 119:624-635
Lukowski R, Rybalkin SD, Loga F, Leiss V, Beavo JA, Hofmann F (2010) Cardiac hypertrophy is
not amplified by deletion of cGMP-dependent kinase-I in cardiomyocytes. Proc Natl Acad Sci
USA 107:5646-5651
Manzur AY, Kuntzer T, Pike M, Swan A (2008) Glucocorticoid corticosteroids for Duchenne
muscular dystrophy. Cochrane Database Syst Rev 1:CD003725
Markham LW, Michelfelder EC, Border WL, Khoury PR, Spicer RL, Wong BL, Benson DW,
Cripe LH (2006) Abnormalities of diastolic function precede dilated ardiomyopathy associated
with Duchenne muscular dystrophy. J Am Soc Echocardiogr 19:865-871
McConell GK, Wadley GD (2008) Potential role of nitric oxide in contraction-stimulated glucose
uptake and mitochondrial biogenesis in skeletal muscle. Clin Exp Pharmacol Physiol
35:1488-1492
McConell GK, Bradley SJ, Stephens TJ, Canny BJ, Kingwell BA, Lee-Young RS (2007) Skeletal
muscle nNOS mu protein content is increased by exercise training in humans. Am J Physiol
Regul Integr Comp Physiol 293:R821-R828
